CD33 and systemic mastocytosis: Currently, CD16 × IL-15 × CD33 TriKE is being evaluated in phase I and II clinical trials in patients with advanced systemic mastocytosis, refractory/relapsed acute myeloid leukemia, or CD33-expressing high-risk myelodysplastic syndromes (NCT03214666).